Specify a stock or a cryptocurrency in the search bar to get a summary
Biovica International AB (publ)
BIOVIC-BBiovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden. Address: Dag Hammarskjölds väg 54B, Uppsala, Sweden, 752 37
Analytics
WallStreet Target Price
232.83 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BIOVIC-B
Dividend Analytics BIOVIC-B
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BIOVIC-B
Stock Valuation BIOVIC-B
Financials BIOVIC-B
Results | 2019 | Dynamics |